Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS.
Recent studies have demonstrated protective effects of alloimmunization in the SIV model. Here, Gene Shearer, Ligia Pinto and Mario Clerici raise the possibility that alloimmunization against a spectrum of HLA-disparate leukocytes be considered for immune-based therapy and as an AIDS vaccine.
Shearer
G M
GM
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Gene_Shearer@nih.gov
Pinto
L A
LA
Clerici
M
M
D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000818:Animals; D017951:Antigen Presentation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D018450:Disease Progression; D015195:Drug Design; D015686:Gene Products, env / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D007114:Immunization; D007962:Leukocytes / Q000276:immunology*; D008251:Macaca / Q000276:immunology; D051379:Mice; D018716:Molecular Mimicry; D051381:Rats; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control / Q000628:therapy; D015302:Simian Immunodeficiency Virus / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D014771:Virion / Q000276:immunology
D016915:AIDS Vaccines; D015686:Gene Products, env; D015488:HIV Antigens; D006680:HLA Antigens